SAMTOR

Summary

SAMTOR (S-adenosylmethionine sensor upstream of mTORC1, HGNC:26475) is a protein-coding gene on chromosome 7q31.1, encoding S-adenosylmethionine sensor upstream of mTORC1 (Q1RMZ1). S-adenosyl-L-methionine-binding protein that acts as an inhibitor of mTORC1 signaling via interaction with the GATOR1 and KICSTOR complexes.

Enables S-adenosyl-L-methionine binding activity. Involved in cellular response to amino acid starvation; cellular response to methionine; and positive regulation of TORC1 signaling. Predicted to be located in cytosol.

Source: NCBI Gene 154743 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 15 total — 1 pathogenic
• MANE Select transcript: NM_152556

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26475
Approved symbol	SAMTOR
Name	S-adenosylmethionine sensor upstream of mTORC1
Location	7q31.1
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp762M126, FLJ31818, SAMTOR
Ensembl gene	ENSG00000164603
Ensembl biotype	protein_coding
OMIM	617855
Entrez	154743

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000297145, ENST00000432572, ENST00000485446, ENST00000967777, ENST00000967778

RefSeq mRNA: 1 — MANE Select: NM_152556 NM_152556

CCDS: CCDS43634

Canonical transcript exons

ENST00000297145 — 5 exons

Exon	Start	End
ENSE00001249485	112819147	112822373
ENSE00001893290	112939591	112939875
ENSE00003461094	112915306	112915447
ENSE00003602759	112895569	112895739
ENSE00003684343	112832561	112832675

Expression profiles

Bgee: expression breadth ubiquitous, 240 present calls, max score 93.80.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.3163 / max 445.3931, expressed in 1784 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
85773	14.1460	1781
85772	1.1702	715

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	93.80	gold quality
cortical plate	UBERON:0005343	91.11	gold quality
oocyte	CL:0000023	89.28	gold quality
cartilage tissue	UBERON:0002418	89.09	gold quality
ganglionic eminence	UBERON:0004023	88.31	gold quality
embryo	UBERON:0000922	88.30	gold quality
amniotic fluid	UBERON:0000173	88.27	gold quality
ventricular zone	UBERON:0003053	87.63	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.56	gold quality
heart right ventricle	UBERON:0002080	87.24	gold quality
endothelial cell	CL:0000115	86.91	gold quality
monocyte	CL:0000576	84.44	gold quality
leukocyte	CL:0000738	84.09	gold quality
calcaneal tendon	UBERON:0003701	83.95	gold quality
Brodmann (1909) area 23	UBERON:0013554	83.75	gold quality
myocardium	UBERON:0002349	83.51	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.42	gold quality
adrenal tissue	UBERON:0018303	83.40	gold quality
middle temporal gyrus	UBERON:0002771	83.11	gold quality
upper leg skin	UBERON:0004262	82.98	gold quality
esophagus squamous epithelium	UBERON:0006920	82.85	gold quality
islet of Langerhans	UBERON:0000006	81.87	gold quality
lower esophagus mucosa	UBERON:0035834	81.75	gold quality
stromal cell of endometrium	CL:0002255	81.30	gold quality
smooth muscle tissue	UBERON:0001135	80.92	gold quality
cauda epididymis	UBERON:0004360	80.29	gold quality
pigmented layer of retina	UBERON:0001782	80.26	gold quality
urinary bladder	UBERON:0001255	79.62	gold quality
tibialis anterior	UBERON:0001385	79.47	silver quality
skin of hip	UBERON:0001554	79.38	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.01

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

195 targeting SAMTOR, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-5688	99.96	73.23	4504

Literature-anchored findings (GeneRIF, showing 1)

• SAMTOR is a S-adenosylmethionine sensor that links methionine and one-carbon metabolism to mTORC1 signaling. (PMID:29123071)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	samtor	ENSDARG00000062181
mus_musculus	Samtor	ENSMUSG00000042742
rattus_norvegicus	Bmt2	ENSRNOG00000007224
drosophila_melanogaster	Samtor	FBGN0035035

Protein

Protein identifiers

S-adenosylmethionine sensor upstream of mTORC1 — Q1RMZ1 (reviewed: Q1RMZ1)

Alternative names: Probable methyltransferase BMT2 homolog

All UniProt accessions (2): Q1RMZ1, H0Y6Y0

UniProt curated annotations — full annotation on UniProt →

Function. S-adenosyl-L-methionine-binding protein that acts as an inhibitor of mTORC1 signaling via interaction with the GATOR1 and KICSTOR complexes. Acts as a sensor of S-adenosyl-L-methionine to signal methionine sufficiency to mTORC1: in presence of methionine, binds S-adenosyl-L-methionine, leading to disrupt interaction with the GATOR1 and KICSTOR complexes and promote mTORC1 signaling. Upon methionine starvation, S-adenosyl-L-methionine levels are reduced, thereby promoting the association with GATOR1 and KICSTOR, leading to inhibit mTORC1 signaling. Probably also acts as a S-adenosyl-L-methionine-dependent methyltransferase (Potential).

Subunit / interactions. Interacts with the DEPDC5 subunit of the GATOR1 complex; interaction is disrupted when SAMTOR binds S-adenosyl-L-methionine. Interacts with the KICSTOR complex; interaction is disrupted when SAMTOR binds S-adenosyl-L-methionine.

Similarity. Belongs to the BMT2/SAMTOR family.

RefSeq proteins (1): NP_689769* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR021867	Bmt2/SAMTOR	Family
IPR029063	SAM-dependent_MTases_sf	Homologous_superfamily

Pfam: PF11968

UniProt features (14 total): binding site 6, mutagenesis site 4, chain 1, region of interest 1, sequence conflict 1, compositionally biased region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
9O5D	ELECTRON MICROSCOPY	3.34

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q1RMZ1-F1	80.02	0.57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (6): 95; 172; 190; 202; 203; 244

Mutagenesis-validated functional residues (4):

Position	Phenotype
175	strongly decreased ability to associate with gator1 and kicstor complexes.
190	abolished binding to s-adenosyl-l-methionine without affecting ability to associate with gator1 and kicstor complexes.
202	abolished binding to s-adenosyl-l-methionine without affecting ability to associate with gator1 and kicstor complexes.
95	abolished binding to s-adenosyl-l-methionine without affecting ability to associate with gator1 and kicstor complexes.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-9639288	Amino acids regulate mTORC1
R-HSA-2262752	Cellular responses to stress
R-HSA-8953897	Cellular responses to stimuli
R-HSA-9711097	Cellular response to starvation

MSigDB gene sets: 184 (showing top): GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_RESPONSE_TO_ACID_CHEMICAL, TGCACTT_MIR519C_MIR519B_MIR519A, GOBP_POSITIVE_REGULATION_OF_TOR_SIGNALING, GOBP_CELLULAR_RESPONSE_TO_ACID_CHEMICAL, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, CAGCTG_AP4_Q5, AAACCAC_MIR140, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, GTGTTGA_MIR505, ATTACAT_MIR3803P, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_CELLULAR_RESPONSE_TO_NITROGEN_COMPOUND, HIF1_Q3, GOBP_CELLULAR_RESPONSE_TO_NUTRIENT

GO Biological Process (13): methylation (GO:0032259), cellular response to amino acid starvation (GO:0034198), cellular response to methionine (GO:0061431), regulation of TORC1 signaling (GO:1903432), negative regulation of TORC1 signaling (GO:1904262), positive regulation of TORC1 signaling (GO:1904263), cytoplasmic translation (GO:0002181), protein-containing complex localization (GO:0031503), cellular response to nutrient levels (GO:0031669), TORC1 signaling (GO:0038202), negative regulation of translational initiation (GO:0045947), positive regulation of translational initiation (GO:0045948), protein localization to lysosome (GO:0061462)

GO Molecular Function (4): methyltransferase activity (GO:0008168), protein-containing complex binding (GO:0044877), S-adenosyl-L-methionine binding (GO:1904047), transferase activity (GO:0016740)

GO Cellular Component (1): cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Cellular response to starvation	1
Cellular responses to stimuli	1
Cellular responses to stress	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
TORC1 signaling	3
regulation of TORC1 signaling	2
translational initiation	2
regulation of translational initiation	2
metabolic process	1
cellular response to starvation	1
response to amino acid starvation	1
cellular response to nutrient	1
cellular response to amino acid stimulus	1
cellular response to nitrogen compound	1
cellular response to oxygen-containing compound	1
response to methionine	1
regulation of TOR signaling	1
negative regulation of TOR signaling	1
positive regulation of TOR signaling	1
translation	1
macromolecule localization	1
response to nutrient levels	1
cellular response to stimulus	1
TOR signaling	1
negative regulation of translation	1
positive regulation of translation	1
protein localization to vacuole	1
transferase activity, transferring one-carbon groups	1
binding	1
cation binding	1
sulfur compound binding	1
catalytic activity	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

686 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SAMTOR	ITFG2	Q969R8	892
SAMTOR	KICS2	Q96MD2	891
SAMTOR	NPRL2	Q8WTW4	849
SAMTOR	CASTOR1	Q8WTX7	764
SAMTOR	SESN2	P58004	754
SAMTOR	SZT2	Q5T011	740
SAMTOR	NPRL3	Q12980	715
SAMTOR	RRAGA	Q7L523	712
SAMTOR	DEPDC5	O75140	707
SAMTOR	SLC38A9	Q8NBW4	678
SAMTOR	KPTN	Q9Y664	670
SAMTOR	RASA1	P20936	621
SAMTOR	RRAGC	Q9HB90	597
SAMTOR	RRAGB	Q5VZM2	509
SAMTOR	WDR59	Q6PJI9	505

IntAct

7 interactions, top by confidence:

A	B	Type	Score
SAMTOR	DEPDC5	psi-mi:“MI:0914”(association)	0.640
SAMTOR	PER1	psi-mi:“MI:0914”(association)	0.530
SAMTOR		psi-mi:“MI:0915”(physical association)	0.370
SAMTOR	MIF4GD	psi-mi:“MI:0914”(association)	0.350
SAMTOR	TMOD1	psi-mi:“MI:0914”(association)	0.350
DISC1	SAMTOR	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (38): DEPDC5 (Affinity Capture-MS), SZT2 (Affinity Capture-MS), C12orf66 (Affinity Capture-MS), NPRL2 (Affinity Capture-MS), NPRL3 (Affinity Capture-MS), ACAD11 (Affinity Capture-MS), ITFG2 (Affinity Capture-MS), KPTN (Affinity Capture-MS), REN (Affinity Capture-MS), PER1 (Affinity Capture-MS), MIF4GD (Affinity Capture-MS), GRN (Affinity Capture-MS), MGEA5 (Affinity Capture-MS), TSR3 (Affinity Capture-MS), TGFBRAP1 (Affinity Capture-MS)

ESM2 similar proteins: A1KXW8, A6QL50, E1BGQ2, H0Y354, O94955, P47224, Q08326, Q0IIH8, Q1JQA1, Q1RMS8, Q1RMZ1, Q2TBU5, Q3T1H6, Q4R372, Q4R528, Q4R9C4, Q5F480, Q5F4A1, Q5I0G3, Q5RCQ0, Q5RFG8, Q5TFE4, Q5TYM5, Q641X7, Q6L9T8, Q6PIP5, Q7L622, Q7Z6J8, Q7ZX59, Q86X60, Q8BFZ8, Q8BKW4, Q8BM85, Q8BX13, Q8CEL2, Q8N5C7, Q8N635, Q8NHU2, Q8TCF1, Q8TCJ0

Diamond homologs: A4IIA7, Q0P410, Q1RMZ1, Q5ZJ87, Q66J91, Q8BXK4, Q9W138

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

15 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	4
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
441861	GRCh37/hg19 7q31.1-31.2(chr7:111642645-115770275)x1	Pathogenic

SpliceAI

1618 predictions. Top by Δscore:

Variant	Effect	Δscore
7:112822370:CACT:C	acceptor_gain	1.0000
7:112822372:CT:C	acceptor_gain	1.0000
7:112822373:TC:T	acceptor_loss	1.0000
7:112822374:C:CC	acceptor_gain	1.0000
7:112822374:C:CG	acceptor_loss	1.0000
7:112822375:T:G	acceptor_loss	1.0000
7:112832555:GCATA:G	donor_loss	1.0000
7:112832556:CATA:C	donor_loss	1.0000
7:112832557:ATACC:A	donor_loss	1.0000
7:112832558:TA:T	donor_loss	1.0000
7:112832559:A:C	donor_loss	1.0000
7:112832674:ACCTA:A	acceptor_loss	1.0000
7:112895563:ACTT:A	donor_loss	1.0000
7:112895565:TTACT:T	donor_loss	1.0000
7:112895566:TACT:T	donor_loss	1.0000
7:112895567:A:AC	donor_gain	1.0000
7:112895567:A:T	donor_loss	1.0000
7:112895567:ACT:A	donor_gain	1.0000
7:112895568:C:CA	donor_gain	1.0000
7:112895568:CT:C	donor_gain	1.0000
7:112895568:CTC:C	donor_gain	1.0000
7:112895568:CTCA:C	donor_gain	1.0000
7:112895568:CTCAG:C	donor_gain	1.0000
7:112895736:TACA:T	acceptor_gain	1.0000
7:112895737:ACA:A	acceptor_gain	1.0000
7:112895738:CA:C	acceptor_gain	1.0000
7:112895738:CAC:C	acceptor_gain	1.0000
7:112895740:C:CC	acceptor_gain	1.0000
7:112915301:CTTA:C	donor_loss	1.0000
7:112915302:TTA:T	donor_loss	1.0000

AlphaMissense

2673 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:112822075:G:T	A296D	1.000
7:112822085:A:G	W293R	1.000
7:112822085:A:T	W293R	1.000
7:112822210:G:T	P251Q	1.000
7:112822217:A:G	Y249H	1.000
7:112822228:A:G	L245P	1.000
7:112832580:T:A	D190V	1.000
7:112832629:A:G	C174R	1.000
7:112832630:G:C	S173R	1.000
7:112832630:G:T	S173R	1.000
7:112832632:T:G	S173R	1.000
7:112832634:C:T	G172D	1.000
7:112832635:C:G	G172R	1.000
7:112832637:A:T	V171D	1.000
7:112915350:C:A	W86C	1.000
7:112915350:C:G	W86C	1.000
7:112915352:A:G	W86R	1.000
7:112915352:A:T	W86R	1.000
7:112915366:A:C	L81W	1.000
7:112915366:A:G	L81S	1.000
7:112915374:C:A	M78I	1.000
7:112915374:C:G	M78I	1.000
7:112915374:C:T	M78I	1.000
7:112915375:A:G	M78T	1.000
7:112915384:G:T	A75D	1.000
7:112915385:C:G	A75P	1.000
7:112915387:T:C	Y74C	1.000
7:112915388:A:G	Y74H	1.000
7:112915425:C:A	W61C	1.000
7:112915425:C:G	W61C	1.000

dbSNP variants (sampled 300 via entrez): RS1000009180 (7:112832831 A>G), RS1000052753 (7:112924116 C>T), RS1000068145 (7:112845114 G>A), RS1000099314 (7:112912673 C>A), RS1000182179 (7:112924423 A>G), RS1000202808 (7:112883331 C>G,T), RS1000213567 (7:112840168 C>G), RS1000276459 (7:112883651 C>T), RS1000300772 (7:112900714 G>A), RS1000313212 (7:112832471 C>T), RS1000318085 (7:112820113 C>G,T), RS1000367899 (7:112851764 G>C), RS1000376233 (7:112858264 A>G,T), RS1000396513 (7:112936597 A>C), RS1000397646 (7:112847516 T>C)

Disease associations

OMIM: gene MIM:617855 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST000253_8	Attention deficit hyperactivity disorder and conduct disorder	5.000000e-06
GCST005851_5	Delirium	1.000000e-07

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases expression	4
trichostatin A	affects cotreatment, decreases expression, affects expression	3
Tobacco Smoke Pollution	increases expression	2
Tretinoin	increases expression	2
Cadmium Chloride	increases abundance, increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
arsenite	affects binding, decreases reaction	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
motexafin gadolinium	increases expression, affects cotreatment	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
PCI 5002	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Air Pollutants	affects expression, increases abundance	1
Cadmium	increases abundance, increases expression	1
Dimethyl Sulfoxide	increases expression	1
Formaldehyde	decreases expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, increases expression	1
Quercetin	decreases expression	1
Silicon Dioxide	decreases expression	1
Silver	increases expression	1
Urethane	increases expression	1
Zinc	affects cotreatment, increases expression	1
Cyclosporine	decreases expression	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice